Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Wilson

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2013
18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft modelSatish K Chitneni, Gerald T Bida, Hong Yuan, et al.
Journal of Medicinal Chemistry|October 14, 2009
Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxinsJared B J Milbank, Ralph J Stevenson, David C Ware, et al.
In Vivo (Athens, Greece)|February 6, 2010
Effectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapyMichael W Epperly, Stephen Y Lai, Anthony J Kanai, et al.
Molecular Cancer Therapeutics|October 8, 2009
Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylatorsWilliam R Wilson, Stephen M Stribbling, Frederik B Pruijn, et al.
Journal of the National Cancer Institute|August 17, 2006
Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugsKevin O Hicks, Frederik B Pruijn, Timothy W Secomb, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2019
Effects of KPC Variant and Porin Genotype on the <i>In Vitro</i> Activity of Meropenem-Vaborbactam against Carbapenem-Resistant <i>Enterobacteriaceae</i>William R Wilson, Ellen G Kline, Chelsea E Jones, et al.
Bioorganic & Medicinal Chemistry|December 28, 2011
Weight loss effects of quaternary salts of 5-amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indoles; structure-activity relationshipsMoana Tercel, Ralph J Stevenson, Guo-Liang Lu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 3, 2021
Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648Cho R Hong, Chantal D Buckley, Way W Wong, et al.
Cancer Chemotherapy and Pharmacology|May 18, 2010
Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in miceYongchuan Gu, Christopher P Guise, Kashyap Patel, et al.
Journal of Medicinal Chemistry|December 28, 2002
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamineMichael P Hay, Swarna A Gamage, Mary S Kovacs, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2013
18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft modelSatish K Chitneni, Gerald T Bida, Hong Yuan, et al.
Journal of Medicinal Chemistry|October 14, 2009
Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxinsJared B J Milbank, Ralph J Stevenson, David C Ware, et al.
In Vivo (Athens, Greece)|February 6, 2010
Effectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapyMichael W Epperly, Stephen Y Lai, Anthony J Kanai, et al.
Molecular Cancer Therapeutics|October 8, 2009
Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylatorsWilliam R Wilson, Stephen M Stribbling, Frederik B Pruijn, et al.
Journal of the National Cancer Institute|August 17, 2006
Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugsKevin O Hicks, Frederik B Pruijn, Timothy W Secomb, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2019
Effects of KPC Variant and Porin Genotype on the <i>In Vitro</i> Activity of Meropenem-Vaborbactam against Carbapenem-Resistant <i>Enterobacteriaceae</i>William R Wilson, Ellen G Kline, Chelsea E Jones, et al.
Bioorganic & Medicinal Chemistry|December 28, 2011
Weight loss effects of quaternary salts of 5-amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indoles; structure-activity relationshipsMoana Tercel, Ralph J Stevenson, Guo-Liang Lu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 3, 2021
Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648Cho R Hong, Chantal D Buckley, Way W Wong, et al.
Cancer Chemotherapy and Pharmacology|May 18, 2010
Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in miceYongchuan Gu, Christopher P Guise, Kashyap Patel, et al.
Journal of Medicinal Chemistry|December 28, 2002
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamineMichael P Hay, Swarna A Gamage, Mary S Kovacs, et al.
Pageof 13